First evidence of cell transplant without immunosuppression
Positive results have been revealed from the first-in-human study transplanting an islet cell therapy into a patient with type 1 diabetes without the use of immunosuppression.
The study was investigating Sana Biotechnology’s UP421, an allogeneic primary islet cell therapy that has been engineered with the company’s hypoimmune (HIP) technology.
Results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin.
C-peptide levels also increase with a mixed meal tolerance test (MMTT), consistent with insulin secretion in response to a meal.
MRI scanning also demonstrated a sustained signal at the site of transplanted cells over time, which is consistent with graft survival. The study identified no safety issues, and the HIP-modified islet cells evaded immune responses.
“The clinical data are highly promising for patients and provide the first evidence in humans for overcoming allogeneic and autoimmune rejection with pancreatic islet cell transplantation in type 1 diabetes with no immunosuppression,” said Per-Ola Carlsson, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. “Today’s data, when combined with progress elsewhere in the field, provide real hope that a scalable, curative treatment for patients with type 1 diabetes, meaning normal blood glucose with no insulin injections or immunosuppression, is possible.”
Sana’s HIP technology is designed to overcome immunologic rejection of allogeneic cells, and in type 1 diabetes, also to evade the autoimmune rejection of pancreatic beta cells.
Steve Harr, Sana’s President and CEO, added: “As far as we are aware, this is the first study showing survival of an allogeneic transplant with no immunosuppression or immune-protective device in a fully immune competent individual.”
Diana Spencer, Senior Digital Content Editor, DDW
